Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
INHCAP (inhibitor of carbonic anhydrase pseudogene) is a human gene officially designated as a pseudogene by the HGNC and Ensembl[1][5][7]. Pseudogenes are stretches of DNA that closely resemble functional genes but usually lack the capacity to produce a functional protein product. INHCAP comes with synonyms such as TFP and TFP1[1][3]. There is no current evidence of biological activity, disease role, drug interaction, or therapeutic relevance assigned to INHCAP in available genetic databases or literature. Therefore, INHCAP is not a valid therapeutic target, and its inclusion as such would be considered incorrect[5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inhibitor of carbonic anhydrase pseudogene (INHCAP).